BioLife Solutions Inc ( (BLFS) ) has released its Q3 earnings. Here is a breakdown of the information BioLife Solutions Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BioLife Solutions Inc., a prominent player in the cell and gene therapy market, specializes in developing and supplying cell processing tools and services that ensure the viability of biologic materials throughout their lifecycle.
In its third-quarter 2025 financial results, BioLife Solutions reported a significant increase in cell processing revenue, marking a 33% rise compared to the same quarter in 2024. The company also highlighted its strategic focus on core cell processing operations following the divestiture of its evo cold chain logistics business.
Key financial metrics for the third quarter include a total revenue of $28.1 million, reflecting a 31% increase from the previous year. The company’s GAAP gross margin stood at 62%, while the non-GAAP adjusted gross margin was 64%. Additionally, BioLife achieved a GAAP net income of $0.6 million and an adjusted EBITDA of $7.8 million, representing 28% of revenue.
BioLife’s strategic initiatives have positioned it as a leading pure-play cell processing company, with a robust product portfolio and a solid financial foundation. The company’s biopreservation media is utilized in a significant portion of ongoing clinical trials in the U.S., and it anticipates further growth with potential approvals for additional products and geographic expansions.
Looking ahead, BioLife Solutions has raised its full-year 2025 revenue guidance for its cell processing platform, expecting continued profitability and value creation. The company remains committed to expanding its market share and enhancing its financial performance through strategic alignments and operational efficiencies.